Nonalcoholic steatohepatitis: Selonsertib has shown improvement in fibrosis stage in patients with moderate to severe fibrosis
Detailed results from an open-label phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor Selonsertib ( formerly GS-4997 ) alone or in combination with the monoclonal antibody Simtuzumab in patients with nonalcoholic steatohepatitis ( NASH ) and moderate to severe liver fibrosis ( fibrosis stages F2 or F3 ), were announced.
The data have demonstrated regression in fibrosis that was, in parallel, associated with reductions in other measures of liver injury in patients treated with Selonsertib for 24 weeks.
These data were presented at The Liver Meeting 2016 in Boston.
Patients receiving Selonsertib demonstrated improvements in several measures of liver disease severity, including fibrosis stage, progression to cirrhosis, liver stiffness ( measured by magnetic resonance elastography, MRE ) and liver fat content ( measured by magnetic resonance imaging (MRI)-proton density fat fraction, PDFF ).
As no differences were observed between combination and monotherapy, results are presented for Selonsertib ( 18 mg and 6 mg ) with/without Simtuzumab and for Simtuzumab alone.
Additionally, patients with fibrosis improvement demonstrated reductions in hepatic collagen content, liver biochemistry ( e.g., serum ALT ) and the apoptosis marker, cytokeratin-18, supporting the biological activity of Selonsertib.
Selonsertib demonstrated no dose-related increases in treatment-emergent adverse events or serious adverse events. Headache, nausea and sinusitis were the most common adverse events in patients receiving Selonsertib.
Currently, no approved treatments exists for NASH, and patients with advanced fibrosis would potentially benefit from new options to halt and/or reverse the progression of their disease.
After only 24 weeks of therapy, Selonsertib exhibited promising anti-fibrotic activity in this study, which was the first known multi-center NASH clinical trial to use centrally-assessed MRE, MRI-PDFF, in addition to liver biopsy as endpoints.
Based on these data, Selonsertib represents an important investigational drug candidate for further clinical trials in patients with NASH and significant fibrosis.
Selonsertib is an investigational small molecule inhibitor of ASK1, a protein that promotes inflammation, apoptosis ( cell death ) and fibrosis in settings of oxidative stress.
Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH.
This phase 2, randomized, open-label trial evaluated the safety, tolerability and efficacy of Selonsertib alone or in combination with Simtuzumab in 72 patients with NASH and fibrosis stages F2 ( n=25 ) or F3 ( n=47 ).
Eligible patients were randomized ( 2:2:1:1:1 ) to receive Selonsertib 6 mg ( n=20 ), Selonsertib 18 mg ( n=22 ), Selonsertib 6 mg plus Simtuzumab 125 mg ( n=10 ), Selonsertib 18 mg plus Simtuzumab 125 mg ( n=10 ) or Simtuzumab 125 mg alone ( n=10 ) for 24 weeks.
Selonsertib was administered orally once daily and Simtuzumab was administered via weekly subcutaneous injection. ( Xagena )
Source: Gilead, 2016
Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a...
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
European Commission has approved Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...
monarchE trial: Abemaciclib given with endocrine therapy has shown improvement compared to endocrine therapy alone in people whose HR+ HER2- early breast cancer is at a high risk of recurrence
Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...
Venclexta as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukemia patients, approved by FDA
The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...
Venetoclax chemotherapy-free combination regimen for patients with previously untreated chronic lymphocytic leukemia
Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months...
The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation, proliferation, metabolism and apoptosis. Increasing body of data...
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...
Combination therapy based on Tafinlar and Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma: approved in European Union
The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...
In 2016, the National Institute for Health and Care Excellence ( NICE ) approved the use of Belimumab ( Benlysta...